HER2-, HER3-, and TROP2-Targeted ADCs: Latest Progress, Future Possibilities, and Advancing the Therapeutic Relational Connection

Gain the latest insights on HER2-, HER3-, and TROP2-targeted ADCs, including their characteristics contributing to differing toxicities, recommendations for monitoring and managing associated adverse effects and strategies for overcoming barriers and disparities for patients prescribed these therapies, through on-demand webcasts with accompanying slides and a ClinicalThought commentary.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca and Gilead Sciences, Inc.

AstraZeneca

Gilead Sciences, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner